Search
All Posts
Why the EU Centralised Procedure Matters More Than Ever
The EU Centralised Procedure (CP) is one of the most powerful mechanisms in global pharmaceutical regulation. A single marketing authorisation application, reviewed by the European Medicines Agency (EMA) and decided by the European Commission, delivers market access across all 27 EU member states simultaneously — plus, through mutual recognition arrangements, in Iceland, Liechtenstein, and Norway. For pharmaceutical and biotechnology companies, it is the most strategically si
Jun 912 min read
EU Pharmaceutical Reform 2026: What's Changing and What It Means for Regulatory Affairs Professionals
The European pharmaceutical landscape is undergoing its most significant transformation in over 20 years. On 6 March 2026, the European Union formally unveiled a sweeping package of pharmaceutical regulatory reforms — updating legislation that had largely remained unchanged since 2004. This is not incremental adjustment; this is a foundational restructuring of how medicines are developed, approved, and made available across all 27 EU Member States. For pharmaceutical compan
Jun 211 min read
What Salaries Can You Expect in Regulatory Affairs in 2026 and other Benefits
As a regulatory affairs professional you can get a starting salary of £50,000 if you are in the UK, $100,000 if you are in the US and €60,000 if you are in Europe. This can increase to £80,000 in the UK, $140,000 in the US and €80,000 in Europe when you reach Manager level. And finally this can go up to £110,000 in the UK, $250,000 in the US and €110,000 in Europe when you reach Director level. In addition to this, your salary can triple with common industry benefits such: An
May 2810 min read
Using NAMs Where They Add Real Regulatory Value
The Shift That Is Redefining Nonclinical Regulatory Science For decades, the nonclinical safety assessment of medicines followed a well-worn path: animal studies, conducted to prescribed protocols, submitted in dossiers shaped by guidelines written largely in the 1980s and 1990s. That path is not disappearing — but it is being fundamentally disrupted by the rise of New Approach Methodologies (NAMs): a broad family of non-animal, human-relevant tools that are now moving from
May 2611 min read
Job Security in the Age of AI: Why Regulatory Affairs is "Future-Proof"
The conversation about artificial intelligence and job security is no longer hypothetical. It is happening right now, in boardrooms, newsrooms, and career counselling sessions around the world. Entire job categories are being reshaped. Roles that seemed permanent a decade ago are being automated. And for anyone building — or considering — a career in the life sciences, the question is unavoidable: Is my career safe? For most professions, that question is genuinely difficult
May 2110 min read
Biosimilars: A Shifting Global Landscape
What Are Biosimilars — And Why Do They Matter? Biosimilars are biological medicines that are highly similar to an already-approved reference biologic — the so-called "originator" — in terms of quality, safety, and efficacy. Unlike generic small-molecule drugs, which can be chemically replicated with near-perfect precision, biologics are large, complex molecules derived from living cells. That complexity means biosimilars are never truly identical to their reference product
May 1910 min read